QT interval prolongation might occur. Rare cases of arrhythmia (including torsade de pointes), cardiac arrest, and sudden death reported, usually in seriously ill patients with comorbidities and/or risk factors (e.g. prior cardiotoxic chemotherapy, cardiomyopathy, electrolyte imbalance, or concomitant QTc-prolonging drugs). Rarely, serious cutaneous reactions, including Stevens-Johnson syndrome, reported with treatment. May cause photosensitivity (especially with long-term use). Visual and/or auditory hallucinations observed. Ocular effects (blurred vision, changes in visual acuity, color perception, and photophobia), commonly associated with treatment. Serious (and rarely fatal) hepatic toxicity (e.g. hepatitis, cholestasis, fulminant failure) observed with azole therapy (use with caution in pre-existing hepatic impairment). Postmarketing reports of pancreatitis in children exist. High potential for CYP-mediated interactions. Avoid or limit use of intravenous formulation in renal impairment (contains excipient sulfobutyl ether β-cyclodextrin, which may accumulate in renal insufficiency). Anaphylactoid-type infusion-related reactions may occur with intravenous dosing. Tablets contain lactose (avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption). Suspension contains sucrose (use caution with fructose intolerance, sucrose-isomaltase deficiency, or glucose-galactose malabsorption).